New Research Suggests Weight Loss Drug May Lower Cancer Risk
Recent studies have shown promising news regarding GLP-1 medications, commonly known for aiding weight loss and managing diabetes. Researchers have discovered that these drugs could also be linked to a reduced risk of certain types of cancers, particularly in women.
A team from Indiana University and the University of Florida looked into the health records of over 86,000 adults with obesity who were prescribed GLP-1 medications. The study, published in JAMA Oncology, found that those who used GLP-1s had a significantly lower overall risk of developing cancer compared to those who did not.
Among the findings, the medications were found to particularly lower the risk of endometrial and ovarian cancers, as well as meningioma, a type of brain tumor. However, it’s important to note that the study did indicate a possible increase in kidney cancer risk associated with GLP-1 use.
Dr. Brian Slomovitz, a gynecologic oncologist at Mount Sinai Medical Center in Miami Beach, commented on the findings, noting that cancers like endometrial and ovarian cancers often stem from obesity. He expressed optimism about the potential of GLP-1 medications, calling them “game-changing” if future studies back up these positive findings.
Dr. Slomovitz highlighted the hormone estrogen, which is produced by fat cells, as a key factor in these cancers. He explained that losing weight can decrease both fat cells and estrogen production, potentially leading to lower inflammation and insulin resistance.
While Dr. Slomovitz does not currently prescribe these medications, he strongly recommends consulting a weight-loss physician or primary care doctor for anyone considering them to ensure safe monitoring of side effects, which can include nausea and pancreatitis.
GLP-1 medications are already being advised for certain cancer survivors to help improve their overall health and prevent future obesity-related diseases. Patients have reported feeling better and more motivated to maintain a healthy lifestyle.
Further research is underway to understand how GLP-1s may affect hormonal issues in women, such as polycystic ovarian syndrome (PCOS), which often contributes to obesity and fertility challenges.
For many patients, the positive effects of these medications extend beyond weight loss, as they report feeling lighter and more energized, leading to a more active lifestyle.
As new studies are conducted, the potential of GLP-1 medications in both weight management and cancer risk reduction continues to spark interest in the medical community.
